Anticonvulsant effects of cannabidiol (CBD), a nonpsychoactive cannabinoid, have not been
investigated in the juvenile brain. We hypothesized that CBD would attenuate epileptiform …

Background and Purpose A non‐psychoactive phytocannabinoid, cannabidiol (CBD), shows
promising results as an effective potential antiepileptic drug in some forms of refractory …

The present study reports the behavioral, electrophysiological, and neuropathological
effects of cannabidiol (CBD), a major non-psychotropic constituent of Cannabis sativa, in the …

Microglia, the dynamic innate immune cells of the central nervous system, become activated
in epilepsy. The process of microglial activation in epilepsy results in the creation of an …

Presently there is no drug therapy for curing epilepsy. Despite many advancements in
epilepsy research, nearly 30% of people with epilepsy remain refractory to current …

Cannabidiol (CBD) is a marijuana compound implicated in epilepsy treatment in animal
models and pharmacoresistant patients. However, little is known about chronic CBD …

Background The treatment of epilepsy during early life poses unique challenges—first-line
therapies leave many individuals with poorly controlled seizures. In response to the …

The influence of cannabidiol (CBD) on brain development is inadequately understood.
Since CBD is considered a non-intoxicating drug, it has attracted great interest concerning …

Cannabinoids have anti-convulsant effects in both in vivo and in vitro models of status
epilepticus. Since the development of spontaneous seizures and neuronal vulnerability are …

Background Epilepsy is one of the most common brain disorder and, despite the possible
use of several therapeutic options, many patients continue to have seizures for their entire …